Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ISAtx-247 (Isotechnika/Roche).

Francis J Dumont1

  • 1Medor Consulting, 421 Dogwood Avenue, Egg Harbor Twp, NJ 08234, USA. francisj_dumont@yahoo.com

Current Opinion in Investigational Drugs (London, England : 2000)
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel pharmacological modulators of autophagy and therapeutic prospects.

Expert opinion on therapeutic patents·2012
Same author

Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.

Current cancer drug targets·2012
Same author

Cytokines: the magic is still there.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Fontolizumab Protein Design Labs.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Fingolimod. Mitsubishi Pharma/Novartis.

IDrugs : the investigational drugs journal·2005
Same author

Technology evaluation: abatacept, Bristol-Myers Squibb.

Current opinion in molecular therapeutics·2004
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

ISAtx-247, a ciclosporin A analog, is being developed as an immunosuppressant to prevent organ rejection and treat autoimmune diseases. A Phase II renal transplant study was completed in June 2003.

Area of Science:

  • Immunology and Pharmacology
  • Transplantation Medicine
  • Autoimmune Disease Research

Background:

  • ISAtx-247 is an analog of ciclosporin A, a widely used immunosuppressant.
  • It is being developed by Isotechnika and Roche.
  • ISAtx-247 aims to prevent organ rejection and treat autoimmune conditions.

Purpose of the Study:

  • To evaluate ISAtx-247 as an immunosuppressant.
  • To assess its potential in preventing organ rejection post-transplantation.
  • To explore its efficacy in treating autoimmune diseases like rheumatoid arthritis, psoriasis, and type 1 diabetes.

Main Methods:

  • A Phase II clinical study was conducted.
  • The study focused on renal transplantation.
  • Data collection and analysis were performed following the study's completion.

Related Experiment Videos

Main Results:

  • A Phase II study in renal transplantation was completed by June 2003.
  • Specific results regarding efficacy and safety are not detailed in the provided abstract.
  • Further clinical development is implied.

Conclusions:

  • ISAtx-247 shows potential as an immunosuppressant agent.
  • The drug is being investigated for transplantation and autoimmune disease applications.
  • Completion of the Phase II study marks a step in its development process.